Rare driver mutations: BRAF- and HER2-mutant NSCLC
BRAF driver mutations in NSCLC are rare at 2 %, but tumours with BRAFV600E mutations have histological features suggestive of aggressive biology. When treated with platinum-based chemotherapy, these patients showed less favourable outcomes. The multi-cohort, non-randomised, phase II BRF113928 study investigated a targeted approach using the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with advanced BRAFV600E-mutated NSCLC.